SanaCurrents on Insmed’s (INSM) entry in pulmonary arterial hypertension (PAH)
Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]
SanaCurrents Pivotal on Humacyte’s (HUMA) regenerative blood vessels
Humacyte, Inc. (NASDAQ:HUMA) Probability Sentiment SUMMARY Regenerative medicine, the therapeutic research devoted to the regrowth [...]
SanaCurrents Speculative on BioAtla’s (BCAB) biologic “switches” in cancer
Bioatla, Inc. (NASDAQ:BCAB) Probability Sentiment SUMMARY Finding the right combination cancer immunotherapy using PD-1, PDL-1 [...]
SanaCurrents on Relmada’s (RLMD) push for REL-1017 to treat depression
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Probability Sentiment SUMMARY While current anti-depressants provide some relief, most physicians [...]
SanaCurrents on Albireo’s (ALBO) approved drug Bylvay to treat Alagille syndrome
Albireo Pharma, Inc. (NASDAQ:ALBO) Probability Sentiment SUMMARY Alagille syndrome (ALGS) is a rare, life-threatening genetic [...]
SanaCurrents on Apellis’ (APLS) clinical rebound to treat rare form of blindness
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Probability Sentiment SUMMARY Apellis Pharmaceuticals is advancing a portfolio of drugs [...]
SanaCurrents Pivotal Sentiment on new Glaukos (GKOS) procedure for rare eye disease
Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.
Amryt receives CRL from the FDA; SanaCurrents closing coverage
UK-based Amryt Pharma plc (NASDAQ:AMYT) said before the market opened on February 28 it had received a complete response letter [...]